Literature DB >> 19932574

Bisphosphonates and atypical femoral fractures: a time for reflection.

J E Compston.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19932574     DOI: 10.1016/j.maturitas.2009.11.002

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


× No keyword cloud information.
  6 in total

1.  Teriparatide for the rapid resolution of delayed healing of atypical fractures associated with long-term bisphosphonate use.

Authors:  Silvina R Mastaglia; Gabriel Aguilar; Beatriz Oliveri
Journal:  Eur J Rheumatol       Date:  2015-08-21

Review 2.  New understanding and treatments for osteoporosis.

Authors:  G Mazziotti; J Bilezikian; E Canalis; D Cocchi; A Giustina
Journal:  Endocrine       Date:  2012-02       Impact factor: 3.633

Review 3.  We need a break: Bisphosphonates.

Authors:  Ashish Jaiman; Dhananjaya Sabat; Sumit Arora; Mahmoud A Hafez
Journal:  J Clin Orthop Trauma       Date:  2013-02-06

Review 4.  Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.

Authors:  Jacques P Brown; Suzanne Morin; William Leslie; Alexandra Papaioannou; Angela M Cheung; Kenneth S Davison; David Goltzman; David Arthur Hanley; Anthony Hodsman; Robert Josse; Algis Jovaisas; Angela Juby; Stephanie Kaiser; Andrew Karaplis; David Kendler; Aliya Khan; Daniel Ngui; Wojciech Olszynski; Louis-Georges Ste-Marie; Jonathan Adachi
Journal:  Can Fam Physician       Date:  2014-04       Impact factor: 3.275

5.  Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database.

Authors:  B Abrahamsen
Journal:  Osteoporos Int       Date:  2012-05-10       Impact factor: 4.507

6.  Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation.

Authors:  Plamen Kinov; Mihail Boyanov
Journal:  Int J Womens Health       Date:  2012-04-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.